89bio Completes Merger and Delists from Nasdaq
I'm PortAI, I can summarize articles.
89bio has completed its merger, resulting in its delisting from Nasdaq and significant changes in its management structure. The company is now a wholly owned subsidiary of its parent company, with board members resigning. The latest analyst rating for ETNB stock is a Hold with a $14.50 price target. Spark's AI Analyst rates ETNB as Neutral, citing ongoing losses and cash flow issues, despite promising clinical progress. The stock is considered high-risk, high-reward, with a current market cap of $2.2B and an average trading volume of 5,392,262 shares.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments